|
Market Closed -
Nasdaq
00:00:00 14/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 14.02 USD | -5.53% |
|
+3.85% | - |
Projected Income Statement: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| Change | - | - | - | - |
| EBITDA 1 | - | -111.5 | -135.7 | -159.4 |
| Change | - | - | -21.65% | -17.5% |
| EBIT 1 | - | -109.7 | -130.1 | -161.5 |
| Change | - | - | -18.54% | -24.15% |
| Interest Paid | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -104.7 | -121.6 | -156.6 |
| Change | - | - | -16.2% | -28.76% |
| Net income 1 | -60.56 | -102.6 | -118.9 | -149.7 |
| Change | - | -69.4% | -15.92% | -25.87% |
| Announcement Date | 4/24/26 A | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Change | - | - | - | - |
| Announcement Date | 4/24/26 A | - | - | - |
Estimates
Cash Flow Forecast: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | 1 | 0.525 | 1 |
| Change | - | -47.5% | 90.48% |
| Free Cash Flow (FCF) 1 | -92 | -113 | -95.45 |
| Change | - | -22.83% | 15.53% |
| Announcement Date | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
Profitability | ||||
| EBITDA Margin (%) | - | - | - | - |
| EBIT Margin (%) | - | - | - | - |
| EBT Margin (%) | - | - | - | - |
| Net margin (%) | - | - | - | - |
| FCF margin (%) | - | - | - | - |
| FCF / Net Income (%) | - | 89.69% | 95.03% | 63.77% |
Profitability | ||||
| ROA | - | -55.29% | -73.62% | -133.66% |
| ROE | - | -71.69% | -105.97% | -277.37% |
Financial Health | ||||
| Leverage (Debt/EBITDA) | - | - | - | - |
| Debt / Free cash flow | - | - | - | - |
Capital Intensity | ||||
| CAPEX / Current Assets (%) | - | - | - | - |
| CAPEX / EBITDA (%) | - | -0.9% | -0.39% | -0.63% |
| CAPEX / FCF (%) | - | -1.09% | -0.46% | -1.05% |
Items per share | ||||
| Cash flow per share 1 | - | - | - | - |
| Change | - | - | - | - |
| Dividend per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| EPS 1 | -5.3 | -5.667 | -3.26 | -3.441 |
| Change | - | -6.92% | 42.47% | -5.54% |
| Nbr of stocks (in thousands) | - | 31,785 | 31,785 | 31,785 |
| Announcement Date | 4/24/26 A | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -2.47x | -4.3x |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.02USD
Average target price
35.40USD
Spread / Average Target
+152.50%
- Stock Market
- Stocks
- BLSM Stock
- Financials BlossomHill Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
